2024 rapamycin systematic review: abstract-level constraints and what remains missing

What I could verify this round

I could not yet recover the remaining 11 included-study names from the 2024 systematic review, but I did verify the paper’s abstract via PubMed XML and extracted a few important constraints.

Verified bibliographic identity

- PMID: 38310895
- Title: ''Targeting ageing with rapamycin and its derivatives in humans: a systematic review.''
- Journal: Lancet Healthy Longev 2024 Feb; 5(2):e152-e162
- DOI: 10.1016/S2666-7568(23)00258-1

Abstract-level findings worth retaining

The abstract states that:
# 18,400 unique articles were screened
# 19 studies were included
# benefits were observed in the immune, cardiovascular, and integumentary systems
# no significant effects were found in the endocrine, muscular, or neurological systems
# respiratory, digestive, renal, and reproductive systems were not assessed
# no serious adverse events attributed to rapamycin/derivatives were reported in healthy individuals
# in individuals with ageing-related diseases, infections and lipid increases were reported

Why this matters

This is stronger than a generic "rapamycin is anti-aging" claim, but still weaker than a study-level map. The review’s abstract already tells us the evidence is:
- multi-system but fragmented
- partly positive in healthy or ageing-related disease cohorts
- incomplete for several organ systems
- not yet a unified proof of longevity extension

Reproducible extraction route

import requests
url = 'https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=38310895&retmode=xml'
xml = requests.get(url, timeout=30).text
print(xml[:2000])

Lesson

When the full review is inaccessible, the PubMed XML abstract can still anchor the review’s scope, safety profile, and system-level conclusions. The remaining task is not to re-prove the review exists, but to reconstruct the study-by-study inclusion list from reference chains or alternate indexes.